Literature DB >> 35747456

Reducing antithrombotic-related bleeding risk in urgent and emergency cardiac surgery.

Amer Harky1, Abdul Badran2.   

Abstract

This review focuses on the role of CytoSorb® (CytoSorbents Corporation, Monmouth Junction, New Jersey, USA), a technology for purifying extracorporeal blood. The technology is designed for several indications to prevent bleeding complications during on-pump cardiac surgery, including removal of the antiplatelet agent, ticagrelor, and the oral anticoagulant, rivaroxaban, from the blood. Recent clinical studies are briefly reviewed.
Copyright © 2021 Medinews (Cardiology) Limited.

Entities:  

Keywords:  CytoSorb®; bleeding; haemoadsorption; resternotomy; rivaroxaban; surgery; ticagrelor; transfusion

Year:  2021        PMID： 35747456      PMCID： PMC8988220          DOI： 10.5837/bjc.2021.026

Source DB:  PubMed          Journal:  Br J Cardiol        ISSN： 0969-6113


  13 in total

Review 1.  What Have We Learned about the Use of Cytosorb Adsorption Columns?

Authors:  Ghada Ankawi; Yun Xie; Bo Yang; Yuanyuan Xie; Pan Xie; Claudio Ronco
Journal:  Blood Purif       Date:  2019-04-30       Impact factor: 2.614

Review 2.  Massive bleeding in cardiac surgery. Definitions, predictors and challenges.

Authors:  A Petrou; P Tzimas; S Siminelakis
Journal:  Hippokratia       Date:  2016 Jul-Sep       Impact factor: 0.471

3.  Cytosorb Adsorption During Emergency Cardiac Operations in Patients at High Risk of Bleeding.

Authors:  Kambiz Hassan; Jochen Kannmacher; Peter Wohlmuth; Ulrich Budde; Michael Schmoeckel; Stephan Geidel
Journal:  Ann Thorac Surg       Date:  2019-01-23       Impact factor: 4.330

Review 4.  Infection and inflammation and the coagulation system.

Authors:  Marcel Levi; Tymen T Keller; Eric van Gorp; Hugo ten Cate
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

5.  Impact of bleeding complications on length of stay and critical care utilization in cardiac surgery patients in England.

Authors:  Nawwar Al-Attar; Stephen Johnston; Nadine Jamous; Sameer Mistry; Ena Ghosh; Gaurav Gangoli; Walter Danker; Katherine Etter; Eric Ammann
Journal:  J Cardiothorac Surg       Date:  2019-04-02       Impact factor: 1.637

6.  Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study.

Authors:  Willem Pieter Brouwer; Servet Duran; Martijn Kuijper; Can Ince
Journal:  Crit Care       Date:  2019-09-18       Impact factor: 9.097

7.  Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb® sorbent porous polymer beads.

Authors:  Maryann C Gruda; Karl-Gustav Ruggeberg; Pamela O'Sullivan; Tamaz Guliashvili; Andrew R Scheirer; Thomas D Golobish; Vincent J Capponi; Phillip P Chan
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

8.  Ticagrelor Removal From Human Blood.

Authors:  George O Angheloiu; Gabriel B Gugiu; Cristian Ruse; Rishikesh Pandey; Ramachandra R Dasari; Carl Whatling
Journal:  JACC Basic Transl Sci       Date:  2017-04-24

9.  Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis.

Authors:  Mehdi Javanbakht; Miranda Trevor; Mohsen Rezaei Hemami; Kazem Rahimi; Michael Branagan-Harris; Fabian Degener; Daniel Adam; Franziska Preissing; Jörg Scheier; Suzanne F Cook; Eric Mortensen
Journal:  Pharmacoecon Open       Date:  2020-06

10.  Operative survival in patients with acute aortic disease in the era of newer oral anticoagulants.

Authors:  Johannes Lagethon Bjørnstad; Adil Mahboob Khan; Henriette Røed-Undlien; Bjørn Bendz; Ståle Nygård; Tom Nilsen Hoel; Per Snorre Lingaas
Journal:  Open Heart       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.